{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:29:44Z","timestamp":1790573384248,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220587"],"award-info":[{"award-number":["RP220587"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008562","name":"The University of Texas at Austin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["F-1767"],"award-info":[{"award-number":["F-1767"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["023740"],"award-info":[{"award-number":["023740"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119113","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:10:30Z","timestamp":1771283430000},"page":"119113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer"],"prefix":"10.1016","volume":"196","author":[{"given":"Dileep R.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5717-6743","authenticated-orcid":false,"given":"McKenna E.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-7708","authenticated-orcid":false,"given":"Yasuaki","family":"Anami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5001-1812","authenticated-orcid":false,"given":"Jayden","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minji","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Tsuchikama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-8486","authenticated-orcid":false,"given":"Jennifer A.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-7275","authenticated-orcid":false,"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-5686","authenticated-orcid":false,"given":"Jangsoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119113_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41523-025-00743-w","article-title":"Novel treatment approaches utilizing antibody-drug conjugates in breast cancer","volume":"11","author":"Davis","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119113_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119113_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tem.2022.02.002","article-title":"The membrane receptor CD44: novel insights into metabolism","volume":"33","author":"Weng","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119113_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119113_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1083\/jcb.128.4.687","article-title":"CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor","volume":"128","author":"Bennett","year":"1995","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119113_bib6","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1101\/gad.242602","article-title":"CD44 is required for two consecutive steps in HGF\/c-Met signaling","volume":"16","author":"Orian-Rousseau","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2026.119113_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119113_bib8","doi-asserted-by":"crossref","first-page":"34876","DOI":"10.18632\/oncotarget.26172","article-title":"High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy","volume":"9","author":"Kagami","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119113_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-022-02314-4","article-title":"Direct interaction of TrkA\/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells","volume":"41","author":"Trouvilliez","year":"2022","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119113_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10120-022-01357-y","article-title":"CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma","volume":"26","author":"Giraud","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.biopha.2026.119113_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mvr.2004.05.001","article-title":"Expression of CD44v3 protein in human endothelial cells in vitro and in tumoral microvessels in vivo","volume":"68","author":"Forster-Horvath","year":"2004","journal-title":"Micro Res"},{"key":"10.1016\/j.biopha.2026.119113_bib12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.27385","article-title":"Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity","volume":"62","author":"Crispin","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biopha.2026.119113_bib13","doi-asserted-by":"crossref","first-page":"20648","DOI":"10.1038\/s41598-023-47891-2","article-title":"Selection, characterization and in vivo evaluation of novel CD44v6-targeting antibodies for targeted molecular radiotherapy","volume":"13","author":"Mortensen","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119113_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003360","article-title":"CD44s and CD44v6 expression in head and neck epithelia","volume":"3","author":"Mack","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119113_bib15","doi-asserted-by":"crossref","first-page":"54157","DOI":"10.18632\/oncotarget.11022","article-title":"DeltaNp63 drives metastasis in breast cancer cells via PI3K\/CD44v6 axis","volume":"7","author":"Di Franco","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119113_bib16","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119113_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e32801403f4","article-title":"Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study","volume":"18","author":"Rupp","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2026.119113_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12282-018-0888-y","article-title":"CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"26","author":"Tokunaga","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119113_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fcell.2020.00417","article-title":"CD44v9 Induces Stem Cell-Like Phenotypes in Human Cholangiocarcinoma","volume":"8","author":"Suwannakul","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119113_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/cas.12908","article-title":"CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma","volume":"107","author":"Kakehashi","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119113_bib21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5966\/sctm.2015-0048","article-title":"Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target","volume":"4","author":"Yan","year":"2015","journal-title":"Stem Cells Transl. Med"},{"key":"10.1016\/j.biopha.2026.119113_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e12566","article-title":"The clinical impact of the expression of the cancer stem cell marker CD44v9 in early triple negative breast cancer (TNBC)","volume":"38","author":"Tokunaga","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119113_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3892\/ol.2022.13200","article-title":"Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis","volume":"23","author":"Kobayashi","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2026.119113_bib24","article-title":"Prognostic value of CD44v9 expression in human cancers: a systematic review and meta-analysis","volume":"99","author":"Zeng","year":"2020","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.biopha.2026.119113_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nmeth.1318","article-title":"Enzymatic assembly of DNA molecules up to several hundred kilobases","volume":"6","author":"Gibson","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2026.119113_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4939-2425-7_14","article-title":"Using light scattering to determine the stoichiometry of protein complexes","volume":"1278","author":"Mogridge","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119113_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119113_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."},{"key":"10.1016\/j.biopha.2026.119113_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/adt.2020.1024","article-title":"A flexible multiplatform bioanalytical strategy for measurement of total circulating shed target receptors: application to soluble B cell maturation antigen levels in the presence of a bispecific antibody drug","volume":"19","author":"Stauffer","year":"2021","journal-title":"Assay. Drug Dev. Technol."},{"key":"10.1016\/j.biopha.2026.119113_bib30","article-title":"Trastuzumab deruxtecan: an antibody-drug conjugate embracing its destiny in breast cancer","volume":"3","author":"Makhlin","year":"2022","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.biopha.2026.119113_bib31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119113_bib32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119113_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody\u2013drug conjugate\u2013resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119113_bib34","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-2930","article-title":"Abstract 2930: intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systems","volume":"85","author":"Sainamthip","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119113_bib35","article-title":"Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters","author":"Roth","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2026.119113_bib36","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-3321","article-title":"Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer","author":"Rampa","year":"2026","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119113_bib37","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:39:39Z","timestamp":1781879979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S0753332226001459"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119113","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119113"}}